Sun Pharma.Inds.

{
  "main_header": {
    "sid": 948699,
    "name": "Sun Pharma.Inds.",
    "stock_name": "Sun Pharma.Inds.",
    "full_name": "Sun Pharmaceutical Industries Ltd",
    "name_url": "stocks-analysis/sun-pharmainds",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,756.35",
    "chg": -21.1,
    "chgp": "-1.19%",
    "dir": -1,
    "prev_price": "1,777.45",
    "mcapval": "423,735.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 524715,
    "symbol": "SUNPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE044A01036",
    "curr_date": "Mar 23",
    "curr_time": "",
    "bse_nse_vol": "28.34 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 23, 2026",
    "traded_date_str": "2026 03 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 35.12 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-nifty-50-membership-and-institutional-dynamics-shape-market-outlook-3906718",
        "imagepath": "",
        "date": "2026-03-23 09:20:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Above Industry Average</strong></p>\n                <p>The stock’s P/E ratio of 35.12 stands approximately 10.1% higher than the sector average of 31.90, signalling that investors are willing to pay a premium for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> relative to its peers. This premium may reflect expectations of superior earnings growth or a perception of stronger fundamentals compared to the broader Pharmaceuticals & Biotechnology sector. However, such a valuation gap also raises questions about sustainability, especially given the sector’s mixed result performance so far in the current reporting season.</p>\n\n                <p><strong>Performance Across Tim..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd Strengthens Position Amid Nifty 50 Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-amid-nifty-50-dynamics-3902452",
        "imagepath": "",
        "date": "2026-03-20 09:21:07",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index confers considerable advantages to Sun Pharmaceutical Industries Ltd, not least in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange of India, serves as a benchmark for institutional and retail investors alike. Inclusion in this elite group often leads to increased demand from index funds and passive investment vehicles, which track the Nifty 50 composition.</p>\n                <p>Sun Pharma’s market capitalisation currently stands at a substantial ₹4,18,528 crores, firmly placing it in the large-cap category. This stature not only reflects its scale but also its resilience..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd: Navigating Nifty 50 Membership and Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-shifts-3899636",
        "imagepath": "",
        "date": "2026-03-19 09:21:15",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index places Sun Pharmaceutical Industries Ltd at the forefront of India’s equity landscape. This membership not only reflects the company’s market capitalisation and liquidity but also ensures heightened visibility among domestic and global investors. Index inclusion often leads to increased institutional interest, as many mutual funds, exchange-traded funds (ETFs), and passive investment vehicles track the Nifty 50, necessitating allocation to its constituents.</p>\n                <p>Sun Pharma’s market capitalisation currently stands at a robust ₹4,25,318.11 crores, firmly categorising it as a large-cap entity. This scale provides the company with a competitive advantage in capita..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sun-pharmaceutical-industries-ltd-is-rated-buy-3898460",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SunPharmaceutic_mojoScore_3898460.png",
        "date": "2026-03-18 10:10:49",
        "description": "Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      },
      {
        "title": "Sun Pharmaceutical Sees Heavy Put Option Activity Ahead of March Expiry",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-heavy-put-option-activity-ahead-of-march-expiry-3898399",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SunPharmaceutic_most_active_stocks_puts_3898399.png",
        "date": "2026-03-18 10:00:15",
        "description": "Sun Pharmaceutical Industries Ltd has emerged as one of the most actively traded stocks in the put options segment as the 30 March 2026 expiry approaches, signalling increased bearish positioning or hedging activity among investors. With a significant volume of contracts traded at the ₹1800 strike price, market participants appear to be positioning cautiously despite the stock’s proximity to its 52-week high."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd: Strengthening Its Position in the Nifty 50 Amid Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthening-its-position-in-the-nifty-50-amid-institutional-shifts-3898167",
        "imagepath": "",
        "date": "2026-03-18 09:21:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index confers considerable prestige and market visibility on Sun Pharmaceutical Industries Ltd. As one of the largest and most liquid stocks in the Indian equity market, its inclusion ensures that the company remains a focal point for both domestic and global institutional investors. Index funds and exchange-traded funds (ETFs) tracking the Nifty 50 are compelled to hold shares of Sun Pharma, thereby providing a steady demand base and enhancing liquidity.</p>\n                <p>This membership also means that the company’s stock performance has a direct bearing on the overall index movement, making it a bellwether for the Pharmaceuticals & Biotechnology sector. Given the sec..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd Strengthens Position as Nifty 50 Constituent Amid Positive Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-as-nifty-50-constituent-amid-positive-momentum-3896026",
        "imagepath": "",
        "date": "2026-03-17 09:20:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index is a hallmark of market leadership and stability. Sun Pharmaceutical Industries Ltd’s inclusion in this benchmark index not only reflects its substantial market capitalisation of ₹4,29,408.98 crores but also its critical role in representing the Pharmaceuticals & Biotechnology sector within India’s equity markets. Index membership ensures enhanced visibility and liquidity, attracting a broad spectrum of investors, including mutual funds, pension funds, and foreign institutional investors who often benchmark their portfolios against the Nifty 50.</p>\n                <p>Moreover, the stock’s large-cap status and consistent presence in the index contribute to its weight in the ove..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd Strengthens Position as Nifty 50 Constituent Amid Robust Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-as-nifty-50-constituent-amid-robust-performance-3892927",
        "imagepath": "",
        "date": "2026-03-16 09:21:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index places Sun Pharmaceutical Industries Ltd at the forefront of India’s equity market, representing one of the 50 most liquid and large-cap stocks. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures inclusion in numerous index-tracking funds and ETFs, thereby increasing liquidity and demand. The company’s market capitalisation of ₹4,33,871.74 crores firmly establishes it as a large-cap entity, a critical criterion for Nifty 50 inclusion.</p>\n                <p>Sun Pharma’s presence in this benchmark index is a testament to its market leadership in the Pharmaceuticals & Biotechnology sector, which remains a vital s..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd Strengthens Position as Nifty 50 Constituent Amid Institutional Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-as-nifty-50-constituent-amid-institutional-shifts-3888262",
        "imagepath": "",
        "date": "2026-03-13 09:21:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index places Sun Pharmaceutical Industries Ltd at the forefront of India’s equity market, representing one of the most liquid and widely tracked benchmarks. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures inclusion in numerous index-linked funds and ETFs, thereby increasing demand and liquidity. The company’s market capitalisation of ₹4,37,879 crores firmly establishes it as a large-cap entity, a critical factor for institutional investors seeking stability and scale.</p>\n                <p>Sun Pharma’s presence in the Nifty 50 also signals its leadership within the Pharmaceuticals & Biotechnology sector, which ha..."
      }
    ],
    "total": 1018,
    "sid": "948699",
    "stock_news_url": "https://www.marketsmojo.com/news/sun-pharmaceutical-industries-948699"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "21-Mar-2026",
      "details": "Sun Pharma launches its semaglutide injection under the brand names Noveltreat and Sematrinity in India",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "18-Mar-2026",
      "details": "Newspaper publication for Notice of Postal Ballot",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Satisfaction Survey On RTA Services",
      "datetime": "17-Mar-2026",
      "details": "Shareholder Satisfaction Survey on RTA Services",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has declared <strong>1100%</strong> dividend, ex-date: 05 Feb 26",
          "dt": "2026-02-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:5</strong> stock split, ex-date: 25 Nov 10",
          "dt": "2010-11-25",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Jul 13",
          "dt": "2013-07-29",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 35.12 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-03-23 09:20:59

Valuation Picture: Premium Above Industry Average

The stock’s P/E ratio of 35.12 stands approximately 10.1% higher than the sector average of 31.90, signalling that investors are willing to pay a premium for Sun Pharmaceutical Industries Ltd relative to its peers. This premium may reflect expectations of superior earnings growth or a perception of stronger fundamentals compared to the broader Pharmaceuticals & Biotechnology sector. However, such a valuation gap also raises questions about sustainability, especially given the sector’s mixed result performance so far in the current reporting season.

Performance Across Tim...

Read full news article

Sun Pharmaceutical Industries Ltd Strengthens Position Amid Nifty 50 Dynamics

2026-03-20 09:21:07

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index confers considerable advantages to Sun Pharmaceutical Industries Ltd, not least in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange of India, serves as a benchmark for institutional and retail investors alike. Inclusion in this elite group often leads to increased demand from index funds and passive investment vehicles, which track the Nifty 50 composition.

Sun Pharma’s market capitalisation currently stands at a substantial ₹4,18,528 crores, firmly placing it in the large-cap category. This stature not only reflects its scale but also its resilience...

Read full news article

Sun Pharmaceutical Industries Ltd: Navigating Nifty 50 Membership and Institutional Shifts

2026-03-19 09:21:15

Significance of Nifty 50 Membership

Being part of the Nifty 50 index places Sun Pharmaceutical Industries Ltd at the forefront of India’s equity landscape. This membership not only reflects the company’s market capitalisation and liquidity but also ensures heightened visibility among domestic and global investors. Index inclusion often leads to increased institutional interest, as many mutual funds, exchange-traded funds (ETFs), and passive investment vehicles track the Nifty 50, necessitating allocation to its constituents.

Sun Pharma’s market capitalisation currently stands at a robust ₹4,25,318.11 crores, firmly categorising it as a large-cap entity. This scale provides the company with a competitive advantage in capita...

Read full news article

Sun Pharmaceutical Industries Ltd is Rated Buy

2026-03-18 10:10:49

Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Read full news article

Sun Pharmaceutical Sees Heavy Put Option Activity Ahead of March Expiry

2026-03-18 10:00:15

Sun Pharmaceutical Industries Ltd has emerged as one of the most actively traded stocks in the put options segment as the 30 March 2026 expiry approaches, signalling increased bearish positioning or hedging activity among investors. With a significant volume of contracts traded at the ₹1800 strike price, market participants appear to be positioning cautiously despite the stock’s proximity to its 52-week high.

Read full news article

Sun Pharmaceutical Industries Ltd: Strengthening Its Position in the Nifty 50 Amid Institutional Shifts

2026-03-18 09:21:18

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index confers considerable prestige and market visibility on Sun Pharmaceutical Industries Ltd. As one of the largest and most liquid stocks in the Indian equity market, its inclusion ensures that the company remains a focal point for both domestic and global institutional investors. Index funds and exchange-traded funds (ETFs) tracking the Nifty 50 are compelled to hold shares of Sun Pharma, thereby providing a steady demand base and enhancing liquidity.

This membership also means that the company’s stock performance has a direct bearing on the overall index movement, making it a bellwether for the Pharmaceuticals & Biotechnology sector. Given the sec...

Read full news article

Sun Pharmaceutical Industries Ltd Strengthens Position as Nifty 50 Constituent Amid Positive Momentum

2026-03-17 09:20:55

Significance of Nifty 50 Membership

Being part of the Nifty 50 index is a hallmark of market leadership and stability. Sun Pharmaceutical Industries Ltd’s inclusion in this benchmark index not only reflects its substantial market capitalisation of ₹4,29,408.98 crores but also its critical role in representing the Pharmaceuticals & Biotechnology sector within India’s equity markets. Index membership ensures enhanced visibility and liquidity, attracting a broad spectrum of investors, including mutual funds, pension funds, and foreign institutional investors who often benchmark their portfolios against the Nifty 50.

Moreover, the stock’s large-cap status and consistent presence in the index contribute to its weight in the ove...

Read full news article

Sun Pharmaceutical Industries Ltd Strengthens Position as Nifty 50 Constituent Amid Robust Performance

2026-03-16 09:21:04

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index places Sun Pharmaceutical Industries Ltd at the forefront of India’s equity market, representing one of the 50 most liquid and large-cap stocks. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures inclusion in numerous index-tracking funds and ETFs, thereby increasing liquidity and demand. The company’s market capitalisation of ₹4,33,871.74 crores firmly establishes it as a large-cap entity, a critical criterion for Nifty 50 inclusion.

Sun Pharma’s presence in this benchmark index is a testament to its market leadership in the Pharmaceuticals & Biotechnology sector, which remains a vital s...

Read full news article

Sun Pharmaceutical Industries Ltd Strengthens Position as Nifty 50 Constituent Amid Institutional Shifts

2026-03-13 09:21:09

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index places Sun Pharmaceutical Industries Ltd at the forefront of India’s equity market, representing one of the most liquid and widely tracked benchmarks. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures inclusion in numerous index-linked funds and ETFs, thereby increasing demand and liquidity. The company’s market capitalisation of ₹4,37,879 crores firmly establishes it as a large-cap entity, a critical factor for institutional investors seeking stability and scale.

Sun Pharma’s presence in the Nifty 50 also signals its leadership within the Pharmaceuticals & Biotechnology sector, which ha...

Read full news article

View All News